Moreover, the re-analyzed data from COVID-19 patients indicated that there was no noticeable bias in the expression of IL-25, IL-33, or other activation molecules related to ILC2s in tuft cells (Fig. 5B through D; Fig. S11). This evidence concerns the gene IL25 and COVID-19.